Imaging Hand Joint Disease in Osteoarthritis and Rheumatoid Arthritis Using a Radioactive Tracer
Tests a radioactive imaging tracer to find diseased hand joints in adults with arthritis.
Plain-language title generated from the registry record
Registry title: Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine
Key facts
- Where
- Clermont-Ferrand, FranceSee the 2 sites
- Phase
- Phase 2
Where in France
- Centre Jean PerrinClermont-Ferrand, FranceNo longer taking part
- CHU Clermont-FerrandClermont-Ferrand, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Jean Perrin
- Trial code
- NCT07624994
- Record updated
- 20 October 2026
- Original description
This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritisRead full original descriptionShow less
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study
This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis
Inclusion: Karnofsky index > 70%; Obtaining written, signed and dated informed consent; Affiliation to a health insurance plan; For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period; Ability and willingness to respect study visits, exams as well as protocol; RA Group:; certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,; symptomatic (finger pain > 4 /10 on a numerical scale),; active synovitis (clinical and ultrasound),; Group DOA:; certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale),; stopping NSAIDs for at least 8 days before the injection,.
Exclusion: Ongoing use of non-steroidal anti-inflammatory drugs,; History of osteoarticular hand surgery; History of hand soft tissue surgery in the past 6 months; History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,; Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study; RA Group:; Patients with a history of hand DOA; Patients or patients 18 years old,; Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,; Pregnant or breastfeeding patient,; IMC>30,; Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,; Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.